Dec 06, 2016 8:00 am EST CymaBay Therapeutics Announces that the Recommended International Nonproprietary Name for MBX-8025 is Seladelpar
Nov 28, 2016 8:00 am EST CymaBay Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference
Nov 10, 2016 4:01 pm EST CymaBay to Host Key Opinion Leader Meeting on Primary Biliary Cholangitis in New York City
Nov 10, 2016 8:00 am EST CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 for the Treatment of Primary Biliary Cholangitis
Nov 09, 2016 8:00 am EST CymaBay Therapeutics Announces a Newly Issued U.S. Patent for the Use of MBX-8025 as a Treatment for Primary Biliary Cholangitis (PBC)
Nov 02, 2016 8:00 am EDT CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9
Oct 20, 2016 2:41 pm EDT CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting
Oct 20, 2016 8:00 am EDT CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines (PRIME) Designation for the Treatment of Primary Biliary Cholangitis
Oct 11, 2016 8:00 am EDT CymaBay Therapeutics Announces a Newly Issued U.S. Patent for MBX-8025 for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)